Omega Therapeutics

Gene Editing

OTX-2101 Clin0 NSCLC; 6 undisclosed programs RD/Clin0 SCLC, IPF, liver regeneration, corneal regeneration, alopecia, undisclosed

Omega Therapeutics is developing RNA therapeutics to reprogram the topology of genomic control. Chromatin structure plays an important role in governing gene expression, which becomes perturbed in disease. Omega is addressing aberrant gene expression by engineering programmable mRNA medicines for precision genomic control using their OMEGA Epigenetic Programming platform. Multiplexing enables the targeting of many genomic sites using Omega’s Epigenomic Controllers to regain optimal gene expression to treat or cure diseases. To develop further tools, Omega uses knowledge of the 3D-genomic organization with transcriptomics and machine learning. Currently, they have multiple programs in preclinical studies for regenerative medicine and immunology.